Chasing AnaptysBio and Lilly, MiroBio rounds up $97M for autoimmune checkpoint agonist clinical trials

Medicxi, OrbiMed and other VCs have joined forces to help MiroBio flip immune checkpoint R&D on its head, committing $97 million to support development of BTLA and PD-1 autoimmune programs that put the British biotech on turf targeted by AnaptysBio and Eli Lilly.